浩峰生技-小分子新藥開發-治療神經退化性疾病

2022-07-20

浩峰生技-小分子新藥開發 ~治療神經退化性疾病~
ALPS Biotech -New drug discovery from Antrodiacinnamomea~ Drug treatment for neurodegenerative diseases~
NLRP3發炎體活化所引起的發炎反應是導致神經退化相關疾病(阿茲海默症,帕金森氏症,亨氏舞蹈症小腦萎縮症.)的重要因素,抑制發炎體活化可以減缓神經退化相關疾病的進程。浩峰生技證實牛樟芝子實體中的三萜類AL-126,能抑制NLRP3發炎體活化,在亨氏舞蹈症疾病小鼠模式上有顯著減缓疾病進程的效果(美國專利)。浩峰生技正進行罕見疾病亨式舞蹈症的新型藥物開發(臨床前研究階段)未來將應用在其他的神經退化疾病上。
Activation of the NLRP3 inflammasome plays an important role in several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease,and spinocerebellar atrophy. Inhibition of inflammasome activation can slow the progression of neurodegenerative diseases. ALPS Biotech. has proved that the triterpenoid AL-126 from the fruiting body of Antrodia cinnamomea can inhibit the activation of NLRP3 inflammasome and significantly slow the disease progression in the mouse model of
Huntington's disease (US patent). ALPS Biotech. discovered new drugs for Huntington's disease (preclinical research stage), which will be applied to other neurodegenerative diseases in future.

地址:台北市南港區研究院路1段130巷99號C棟6樓R624

聯絡電話:+886-2-27887626

聯絡傳真:+886-2-23788043